A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Active Lupus Nephritis
In brief
The study is a Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with lupus nephritis (LN). It adopts a randomized, double-blind, placebo-controlled, multicenter trial design.
Key facts
- Study ID
- NCT07229742
- Run by
- Guangdong Hengrui Pharmaceutical Co., Ltd
- People needed
- 51
- Starts
- 2025-11-22
- Expected to finish
- 2028-03-01
- Last updated by the study team
- 2025-12-01
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18-70 years (inclusive) at informed consent signing, regardless of sex;
- Body weight ≥ 40.0 kg and body mass index (BMI) ≥ 16 kg/m² to ≤ 28 kg/m² at screening;
- Diagnosed with systemic lupus erythematosus (SLE) per 1997 ACR criteria or 2019 EULAR/ACR classification criteria;
- Positive antinuclear antibody (titer ≥ 1:80) and/or anti-dsDNA antibody and/or anti-Sm antibody at screening;
- Histologically confirmed active lupus nephritis (LN) class III or IV ± class V by renal biopsy, per 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) standards within 1 year preceding or during screening.
You may not qualify if…
- Received renal dialysis within 12 months preceding screening, or anticipated requirement for dialysis/renal transplantation within 6 months post-enrollment;
- Renal biopsy demonstrating > 50% globally sclerosed glomeruli;
- Active severe/unstable neuropsychiatric SLE (NPSLE);
- Catastrophic antiphospholipid syndrome (APS) within 12 months pre-screening, or APS-related thrombotic events (except non-catastrophic/mild APS cases with stable anticoagulation ≥12 weeks prior to screening);
- Non-LN renal diseases potentially confounding disease assessment (e.g., diabetic nephropathy per investigator judgment);
- Inflammatory/autoimmune diseases beyond SLE/LN that may interfere with efficacy/safety interpretation.
Where it is running
- The General Hospital of the Eastern Theater Command of the People's Liberation Army of China — Nanjing, Jiangsu, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.